Name: Neumora Therapeutics, Inc. (NMRA) Financial Statements
Creator: FinSpry

Neumora Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Neumora Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	200.93	142.72	104.75	55.78	17.31
Selling, General & Administrative	62.54	45.48	31.12	24.55	8.39
Operating Expenses	263.46	188.19	135.87	80.32	25.71
Operating Income	-263.46	-188.19	-135.87	-80.32	-25.71
Other Income/Expense
Interest Income	19.93	16.61	4.56	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	19.86	-0.17	0.41	0.01	-0.08
Income
Income Before Tax	-243.61	-235.66	-130.90	-237.31	-99.27
Income Tax Expense	0.18	0.27	0.00	0.00	0.00
Net Income	-243.79	-235.93	-130.90	-237.31	-99.27
Net Income - Continuous Operations	-243.79	-235.93	-130.90	-237.31	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-262.83	-187.53	-135.28	-79.79	-25.60
EBIT	-243.61	-188.19	-135.87	-80.32	-25.71
Depreciation & Amortization	0.63	0.67	0.59	0.54	0.11
Earnings Per Share
Basic EPS	-2.00	-4.00	-1.00	-11.00	-8.00
Diluted EPS	-2.00	-4.00	-1.00	-11.00	-8.00
Basic Shares Outstanding	159.38	65.02	151.95	21.90	13.00
Diluted Shares Outstanding	159.38	65.02	151.95	21.90	13.00